4M Therapeutics to Present at the Upcoming Society of Biological Psychiatry 2026 Annual Meeting

SKILLMAN, N.J. -- 4M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company’s CEO, Pablo Lapuerta, M.D., will present a poster at the upcoming Society of Biological Psychiatry (SOBP) 2026 Annual Meeting taking place on April 30 -May 2, 2026, in New York City.

Details of the poster presentation are below:

SOBP 2026 Annual Meeting

• Title: Advancing Small Molecule Glycogen Synthase 3β (GSK3β) Inhibitors for the Treatment of Bipolar Disorder: Pre-Clinical Target Engagement

• Poster Number: T99

• Session Date and Time: Poster Session 1: Thursday, April 30, 2026 from 5:30 – 7:30 PM ET

About 4M Therapeutics Inc.

4M Therapeutics Inc. (4MTx) is advancing treatments for neuropsychiatric and neurodegenerative conditions. The Company focuses on targets for a wide array of disorders and indications. 4MTx applies unique insights from its living human brain cell platform, which was developed through a collaboration between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. The Company’s pipeline includes potential breakthrough treatments for bipolar mania, agitation in Alzheimer’s disease, neurodegeneration, and other CNS disorders. For more information, visit www.4mtx.net.

Contacts

For investor and media inquiries, please contact:
Kimberly Lee, DO
Chief Business Officer
ir@4mtx.net